Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

peginterferon alfa-2a × Dermatologic × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

pembrolizumab 30 Nivolumab 29 Specimen Handling 19 Magnetic Resonance Spectroscopy 17 Ipilimumab 16 Biopsy 13 Cyclophosphamide 11 trametinib 10 cemiplimab 6 CTLA-4 Antigen 6 fludarabine phosphate 5 fludarabine 5 encorafenib 5 binimetinib 5 relatlimab 4 dabrafenib 4 Radiosurgery 4 tebentafusp 3 naporafenib 3 cabozantinib 3 atezolizumab 3 Vemurafenib 3 Standard of Care 3 Paclitaxel 3 Opdualag 3 Introns 3 Interferon alpha-2 3 Immunoglobulin G 3 Dacarbazine 3 Carboplatin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07288112 2026-02-23

DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

Diakonos Oncology Corporation

Phase 1/2 Recruiting

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡